Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


New stroke-prevention drug unlikely to be cost-effective except in patients at high risk of bleeding


A new study has shown a stroke-prevention drug designed to be an improvement over prior treatments is less cost-effective for most patients than warfarin, the blood thinner with a 50-year history of helping prevent blood clots and strokes. The study, conducted by researchers at Washington University School of Medicine in St. Louis found, however, that the new drug would be cost-effective for those atrial fibrillation patients whose risk of bleeding is high. The findings are reported in the February 9 issue of the Journal of the American Medical Association.

In patients with atrial fibrillation, the upper part of the heart often quivers instead of beating, so blood pools and clots in the upper chambers. The blood clots tend to be large and can travel to the brain causing massive strokes.

AstraZeneca, the company that developed Exanta, had submitted a New Drug Application to the Food and Drug Administration for approval of the drug as an agent to prevent strokes in patients with atrial fibrillation as well as to prevent blood clots in other conditions. The drug was intended as an alternative to warfarin.

In October 2004, the FDA denied Exanta approval. The agency noted that Exanta carried a small risk of liver damage and cited insufficient evidence that it was as effective as warfarin for preventing strokes. "Warfarin is extremely effective," says lead author Brian F. Gage, M.D., associate professor of medicine. "It lowers the risk of stroke by 65 percent. Unfortunately, patients have different sensitivities to warfarin, so it’s difficult to adjust the dose, especially when initiating the drug. While they’re on warfarin, patients’ blood clotting has to be monitored often, and patients find that inconvenient. Warfarin also interacts with various foods and other drugs. Moreover, it doubles the risk of hemorrhage."

Before Exanta, the alternative for patients unable to tolerate warfarin was aspirin, which is not nearly as good as warfarin at preventing blood clots and strokes. "Physicians would like to have a drug that’s as effective as warfarin but doesn’t require monitoring and is less likely to cause bleeding," Gage says. "That’s why there was so much interest in Exanta--it reduces the risk of major hemorrhage by 26 percent and doesn’t have warfarin’s interactions or dosing problems."

The current study was undertaken to provide physicians with a rational way to choose among the three potential therapies. "Since each drug has its own drawbacks, trying to compare them was like comparing apples and oranges," Gage says. "We needed a common currency to make the comparison, so we accounted for quality of life factors and analyzed the way each drug affected quality-adjusted survival."

Gage and Washington University medical student Cara O’Brien compiled data from patients with atrial fibrillation and from the doctors that treated them, adjusting their ranking of each drug based on quality of life measures. They quantified the risk for adverse health conditions such as mild, moderate or severe stroke and looked at other factors that affect quality of life such as the need for multiple tests and ease of taking the medication.

O’Brien and Gage found that warfarin and Exanta were equivalent for preventing strokes and both were better than aspirin. The difference in quality of life measures among the three drugs was small. However, because of its higher price, Exanta was not cost-effective for most patients: the small gain in quality of life did not make up for the higher price in patients at low risk of bleeding.

On the other hand, the study showed that in patients with a high risk of bleeding as well as a significant risk of stroke, Exanta could increase quality of life and thereby increase its cost-effectiveness to a level that is acceptable by current U.S. health-care standards. "We have a lot of octogenarians with atrial fibrillation and a high risk of bleeding, for example, because they tend to fall, have kidney disease or are taking anti-inflammatory medicine," Gage says. "In fact, close to a million Americans with atrial fibrillation are at relatively high risk for hemorrhage. For many of these people, Exanta would be cost-effective."

Exanta has been approved for use in about ten European countries, and observers believe AstraZeneca may soon appeal the FDA’s original ruling and again seek approval for the drug in the U.S.

Gwen Ericson | EurekAlert!
Further information:

More articles from Studies and Analyses:

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Space observation with radar to secure Germany's space infrastructure

Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.

The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

New solar solutions for sustainable buildings and cities

23.03.2018 | Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

Latest News

For graphite pellets, just add elbow grease

23.03.2018 | Materials Sciences

Unique communication strategy discovered in stem cell pathway controlling plant growth

23.03.2018 | Agricultural and Forestry Science

Sharpening the X-ray view of the nanocosm

23.03.2018 | Physics and Astronomy

Science & Research
Overview of more VideoLinks >>>